Iran's supreme leader is ‘unconscious’ - Times

 

The Times reports that Iran’s Supreme Leader Mojtaba Khamenei is unconscious and receiving treatment in the city of Qom, citing a US–Israeli intelligence memo shared with Arab allies.

According to the report, the memo states that Khamenei is currently unable to govern and is undergoing treatment in the religious center south of Tehran.

The newspaper said the information has been circulated among regional partners and may represent the first indication of Khamenei’s location since the war began.

Khamenei has not appeared publicly since the conflict between Iran, the United States and Israel erupted more than five weeks ago.

https://www.iranintl.com/en/liveblog/202604067622

Iran urges UAE, Saudi Arabia, to stop use of territory against it

 

Iran’s ambassador to the United Nations has called on Saudi Arabia and the United Arab Emirates to respect principles of good neighborliness and prevent their territory from being used against Iran.

In two separate letters sent to the UN Security Council and the UN secretary-general, the envoy warned against the continued use of the two countries’ territory for actions targeting Iran.

https://www.iranintl.com/en/liveblog/202604067622

85 arrested over aiding US-Israel strikes, Iran police says

 

Iran’s police chief said on Tuesday that authorities had arrested 85 people after identifying an alleged enemy-linked network in 25 provinces.

Police Commander Ahmadreza Radan accused the detainees of collecting and sending the locations of sensitive sites, including checkpoints and security forces’ positions, for use in strikes by the US and Israel.

He said the authorities had also seized “specialized electronic equipment, Starlink devices, weapons and ammunition.”

https://www.iranintl.com/en/liveblog/202604067622

Kurdistan region says drones that killed couple in Erbil were launched from Iran

 

The Iraqi Kurdistan region’s counter-terrorism service said on Tuesday that drones which struck a civilian home in Erbil overnight, killing a couple, were launched from Iran.

In a statement issued early on Tuesday, the agency said the one-way attack drones targeting Erbil had taken off from inside Iranian territory.

The presidency of the Kurdistan region called on the Iraqi federal government to take responsibility to prevent such attacks and stop what it described as repeated violations against the region and its civilians.

The governor of Erbil said multiple drones and missiles were fired toward the city overnight.

He said the deaths of the couple brought the total number of people killed in attacks on the Kurdistan region since Feb. 28 to 16.

https://www.iranintl.com/en/liveblog/202604067622

Israel says it hit petrochemical site in Iran

 The Israel Defense Forces (IDF) said on Tuesday that they struck a petrochemical facility in the Iranian city of Shiraz, claiming that it is "one of the few remaining complexes" making chemical components for explosives and ballistic missiles in the country.

The IDF said the attack was carried out yesterday as part of an "extensive strike mission." In addition, the Israeli military said it hit a ballistic missile array in northwestern Iran, which was used to launch rockets toward Israel.

https://breakingthenews.net/Article/Israel-says-it-hit-petrochemical-site-in-Iran/66019116

HUM, UNH, CVS: Healthcare Stocks Soar on 2.48% Medicare Rate Increase

 Stocks of leading healthcare companies jumped more than 10% on April 6 after the Centers for Medicare and Medicaid Services announced a 2.48% rate increase for private insurers in 2027.

Other stocks that are up 10% or more on news of the new Medicare rate increase include UnitedHealth Group UNH +1.48% ▲ , CVS Health CVS -0.29% ▼ and Elevance Health ELV +0.62% ▲ . The final rate represents a meaningful improvement over the initial rates the agency proposed in January of this year.

https://www.tipranks.com/news/hum-unh-cvs-healthcare-stocks-soar-on-2027-medicare-rate-increase

Sanofi’s lunsekimig met primary and key secondary endpoints in phase 2 in asthma and CRSwNP

Sanofi’s lunsekimig met primary and key secondary endpoints in phase 2 respiratory studies in asthma and CRSwNP

The AIRCULES phase 2b study achieved its primary and key secondary endpoints in moderate-to-severe asthma regardless of biomarker status


The DUET phase 2a study met its primary and key secondary endpoints in chronic rhinosinusitis with nasal polyps, reinforcing lunsekimig’s potential as a respiratory treatment


The exploratory VELVET phase 2b study did not meet its primary endpoint in moderate-to-severe atopic dermatitis


In all studies, lunsekimig was well tolerated

https://finance.yahoo.com/sectors/healthcare/articles/press-release-sanofi-lunsekimig-met-050000659.html